KETAMINE FOR POSTPARTUM DEPRESSION
Ketamine Therapy for Postpartum Depression in Scottsdale
Postpartum depression affects approximately 1 in 7 new mothers. When standard treatments haven't worked quickly enough — or at all — ketamine offers a mechanistically distinct option that can produce meaningful relief within hours, not weeks.
Understanding Postpartum Depression
PPD is distinct from the "baby blues," which typically resolves within two weeks. It is a clinical condition characterized by persistent low mood, intense anxiety, difficulty bonding, intrusive thoughts, and significant fatigue — and it can emerge within weeks of delivery or up to a year postpartum. Left untreated, it can persist for years.
The biology involves a precipitous postpartum drop in estrogen and progesterone, combined with disrupted neuroplasticity, sleep deprivation, and the psychological weight of new parenthood. PPD affects roughly 10–15% of new mothers (CDC, 2020). Risk factors include a personal history of depression, a difficult delivery, inadequate support, and significant life stressors.
Why Standard Treatments Sometimes Fall Short
SSRIs are effective for many patients but require 4–6 weeks to work — a meaningful delay during the bonding period. Brexanolone (Zulresso) and zuranolone (Zurzuvae) are FDA-approved specifically for PPD and act faster, but brexanolone requires a 60-hour in-hospital IV infusion, and zuranolone coverage is inconsistent and costly.
For mothers with treatment-resistant PPD — those who haven't responded to at least one antidepressant trial — standard options narrow considerably. This is where ketamine becomes relevant.
Ketamine for Postpartum Depression
Ketamine acts through the glutamate/NMDA system — distinct from serotonin — and promotes neuroplasticity, which may be particularly relevant during the postpartum period when the brain is already undergoing significant neurobiological change. In published ketamine research, patients have reported meaningful improvements within 24 hours of infusion — a timeline that matters when a mother is struggling to bond with a newborn. Individual results vary.
The evidence base for ketamine in PPD is growing. Ketamine's effectiveness in treatment-resistant depression more broadly is well established, and a growing body of research specifically supports its use in peripartum depression.
Breastfeeding Considerations
Ketamine passes into breast milk, so breastfeeding mothers should pump and discard milk for at least 24 hours after each session before resuming nursing. This is a real practical consideration — Dr. Zabel will help you plan sessions to minimize disruption to your feeding routine. For mothers who are formula-feeding or have already weaned, this does not apply.
What Treatment Looks Like
Treatment begins with a free physician intake covering your obstetric history, medications, psychiatric history, and breastfeeding status. If appropriate, the standard protocol is 4–6 IV infusions over 2–3 weeks, physician-supervised throughout. We encourage coordination with your OB/GYN or perinatal psychiatrist and are happy to communicate with them directly — with your consent. For patients with TRD, Spravato may also be an option and may be covered by insurance. See our pricing page for costs.
Frequently Asked Questions
Is it safe while breastfeeding?↓
Ketamine passes into breast milk, so breastfeeding mothers should pump and discard milk for at least 24 hours after each session. Dr. Zabel will help you time sessions to minimize disruption. For formula-feeding mothers, this does not apply.
How quickly might I see results?↓
In ketamine clinical trials, patients have reported meaningful improvements within 24 hours of first infusion — in sharp contrast to SSRIs, which take 4–6 weeks. A full induction series is designed to build and sustain those effects. Individual results vary.
How does this compare to Zuranolone or Brexanolone?↓
Both target neurosteroid pathways and are FDA-approved specifically for PPD. They're worth discussing with your OB/GYN. Ketamine targets a different mechanism — the glutamate/NMDA system — and is not FDA-approved specifically for PPD. For patients who haven't responded to other treatments, it offers a distinct option. These treatments aren't mutually exclusive.
Do I need a referral?↓
No referral is required. That said, we strongly encourage coordination with your existing providers. Dr. Zabel will communicate with your OB/GYN, midwife, or perinatal psychiatrist — with your consent — to ensure aligned care.
Can I continue my current antidepressant?↓
In most cases, yes. Some medications require evaluation or adjustment prior to treatment, assessed during intake. Dr. Zabel reviews your full medication list as part of the consultation.
The intake is free. Bring your questions — there are no wrong ones.
Book Free Physician Intake